Search results
Fulcrum Therapeutics (NASDAQ:FULC) Raised to Buy at The Goldman Sachs Group
ETF DAILY NEWS· 12 hours agoThe Goldman Sachs Group upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC – Free Report) from a neutral rating to a buy rating in a report issued on Monday, Benzinga reports ...
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Reaffirmed by HC Wainwright
ETF DAILY NEWS· 12 hours agoFulcrum Therapeutics (NASDAQ:FULC – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Tuesday, Benzinga reports ...
Earnings call: Fulcrum Therapeutics partners with Sanofi on FSHD drug By Investing.com
Investing.com· 3 days agoFulcrum Therapeutics (ticker: NASDAQ:FULC) has entered into a significant collaboration with Sanofi...
Fulcrum Therapeutics stock target lifted, maintains buy on Sanofi deal By Investing.com
Investing.com· 3 days agoOn Monday, Stifel, a financial services firm, raised its price target on shares of Fulcrum...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the...
Morningstar· 3 days agoFulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives ...
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 2 days agoWe can compare a company's cash burn to its market capitalisation to get a sense for how many new...
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
BioPharma Dive via Yahoo Finance· 3 days agoThe deal gives the pharma partial rights to a medicine GSK once developed for heart disease but...
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
GuruFocus.com via Yahoo Finance· 3 days agoConversely, general and administrative expenses decreased from $11.5 million to $10.1 million,...
Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod
RTT News· 3 days agoUnder the deal, Fulcrum retains full U.S. commercialization rights, while Sanofi obtains exclusive commercialization rights for losmapimod outside of the ...
Opinion | In Europe, Xi Jinping accomplished exactly what he needed to for China
South China Morning Post· 5 hours agoPerhaps most important from Xi’s perspective was the opportunity to highlight the shared distress...